ABC News and Press, AmerisourceBergen Corporation From 06/07/22

Glenview Capital Management’s 13F portfolio value increased from $4.69B to $4.94B this quarter. The number of positions increased from 57 to 60. They increased Cigna, DXC Technology, Fiserv, US Foods Holding, Amazon.com, and Aptiv plc while decreasing McKesson, Bausch Health, F...

Market timing can be a very attractive and tempting strategy in theory, particularly in challenging markets like today but can be difficult to achieve in real-time. “Factor momentum” is using the recent price action of a given factor (value, growth, quality, etc.) to pre...

BofA's quantamental Alpha Surprise Portfolio saw an equal number of addition and deletions for May. The portfolio return was +2.3% for the month, outperforming the S&P 500 (SP500) (SPY), which was flat, and the equal weight S&P 500 (RSP), +0.8% for the month. The l...

Global healthcare solutions leader well positioned to drive long-term, sustainable growth AmerisourceBergen Corporation (NYSE: ABC) today hosted an investor day event in New York City. Steven H. Collis, Chairman, President & Chief Executive Officer; James F. Cleary, EVP ...

AmerisourceBergen (NYSE:ABC) shares are down ~4% in Wednesday afternoon trading as the company provided future projections at its investors day. The pharma wholesaler reaffirmed its previously issued guidance for fiscal 2022 of $10.80 – $11.05 adjusted diluted earnings per sh...

Ahead of its investor day on Wednesday, pharmaceutical distributor AmerisourceBergen (NYSE:ABC) disclosed its plans to repurchase up to $1B of its outstanding shares of common stock. The program authorized by the company’s board of directors in May is subject to market conditions, Amer...

Company reiterates guidance for fiscal 2022 The Board of Directors authorized a new $1.0 billion share repurchase program AmerisourceBergen Corporation (NYSE: ABC) today reiterated its previously provided guidance for fiscal year 2022 and announced that its Board of ...

AmerisourceBergen is a leading global drug distributor with a strong focus on operational excellence. The company has recently resolved the majority of its legal troubles related to the Opioid crisis, and is now free to continue growing its business. I also highlight the dividend,...

I was bullish about Cardinal Health but sold my position recently. While I consider the stock still undervalued, the moat might get weaker. It might be a mistake to focus just on the economic moat and ignore management and the existence of a growth strategy. For further deta...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...